Search hospitals > Washington > Seattle

Virginia Mason Medical Center

Claim this profile
Seattle, Washington 98101
Global Leader in Pancreatic Cancer
Global Leader in Prostate Cancer
Conducts research for Cancer
Conducts research for Lung Cancer
Conducts research for Breast Cancer
506 reported clinical trials
25 medical researchers
Photo of Virginia Mason Medical Center in SeattlePhoto of Virginia Mason Medical Center in Seattle

Summary

Virginia Mason Medical Center is a medical facility located in Seattle, Washington. This center is recognized for care of Pancreatic Cancer, Prostate Cancer, Cancer, Lung Cancer, Breast Cancer and other specialties. Virginia Mason Medical Center is involved with conducting 506 clinical trials across 644 conditions. There are 25 research doctors associated with this hospital, such as Huong T. Pham, David Aboulafia, MD, Vincent Picozzi, MD, and Hagen F. Kennecke.

Area of expertise

1Pancreatic Cancer
Global Leader
Virginia Mason Medical Center has run 56 trials for Pancreatic Cancer. Some of their research focus areas include:
Stage IV
Stage III
KRAS positive
2Prostate Cancer
Global Leader
Virginia Mason Medical Center has run 45 trials for Prostate Cancer. Some of their research focus areas include:
Stage IV
PD-L1 positive
Stage II

Top PIs

Clinical Trials running at Virginia Mason Medical Center

Lung Cancer
Pancreatic Cancer
Bladder Cancer
Cancer
Breast Cancer
Brain Tumor
Heart Failure
Stroke
Crohn's Disease
Hypertrophic Cardiomyopathy
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

LY3537982 + Immunotherapy/Chemotherapy

for Non-Small Cell Lung Cancer

This trial is testing a new drug, LY3537982, combined with standard treatments for patients with advanced lung cancer that have a specific genetic mutation. The goal is to see if this combination works better than the usual treatments alone.
Recruiting1 award Phase 314 criteria
Image of trial facility.

Amivantamab

for Non-Small Cell Lung Cancer

The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).
Recruiting1 award Phase 219 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Virginia Mason Medical Center?
Where is Virginia Mason Medical Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does Virginia Mason Medical Center accept?
What awards or recognition has Virginia Mason Medical Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security